Miura Tomofumi, Matsumoto Yoshihisa, Motonaga Shinya, Hasuo Hideaki, Abe Keiko, Kinoshita Hiroya
Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa
Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa.
Jpn J Clin Oncol. 2014 Nov;44(11):1082-7. doi: 10.1093/jjco/hyu137. Epub 2014 Sep 23.
Most cancer patients become increasingly anxious toward the end of their life. The objective of this study was to identify predictors of increased opioid dosage in the last week of a terminal cancer patient's life.
We retrospectively reviewed charts of patients who died in our palliative care unit. We assigned the patients to increased group or decreased group according to changes in oral morphine equivalent dosage in their last 7 days. Logistic regression analysis was used to identify predictors of increased oral morphine equivalent dosage.
We analyzed data of 158 patients (female: 43.7%, median age: 64 years). The median oral morphine equivalent dosages on Days 7 and 1 before death were 50 mg (interquartile range: 24-122) and 61 mg (28-129), respectively. Independent predictors of increased oral morphine equivalent dosage included dyspnea (odds ratio: 11.5, 95% confidence interval: 4.98-28.83, P < 0.01), age <65 years (odds ratio: 2.3, 95% confidence interval: 1.04-5.26, P = 0.04) and oral morphine equivalent dosage <50 mg on Day 7 before death (odds ratio: 3.7, 95% confidence interval: 1.68-8.89, P < 0.01). The median oral morphine equivalent dosages on Days 7 and 1 before death were 48 mg (interquartile range: 20-126) and 75 mg (36-170) in patients with dyspnea, and 50 mg (25-120) and 57 mg (25-124) in patients with pain, respectively.
Dyspnea, relative youth and oral morphine equivalent dosage <50 mg on Day 7 before death were predictive of increased oral morphine equivalent dosage in the last 7 days. Our findings may help oncologists to more accurately inform patients about expected opioid requirements and thus relieve their end-of-life anxiety.
大多数癌症患者在生命末期会越来越焦虑。本研究的目的是确定晚期癌症患者生命最后一周阿片类药物剂量增加的预测因素。
我们回顾性地查阅了在我们姑息治疗病房死亡患者的病历。根据患者最后7天口服吗啡当量剂量的变化,将其分为剂量增加组或剂量减少组。采用逻辑回归分析来确定口服吗啡当量剂量增加的预测因素。
我们分析了158例患者的数据(女性:43.7%,中位年龄:64岁)。死亡前第7天和第1天的口服吗啡当量中位数分别为50毫克(四分位间距:24 - 122)和61毫克(28 - 129)。口服吗啡当量剂量增加的独立预测因素包括呼吸困难(比值比:11.5,95%置信区间:4.98 - 28.83,P < 0.01)、年龄<65岁(比值比:2.3,95%置信区间:1.04 - 5.26,P = 0.04)以及死亡前第7天口服吗啡当量剂量<50毫克(比值比:3.7,95%置信区间:1.68 - 8.89,P < 0.01)。呼吸困难患者死亡前第7天和第1天的口服吗啡当量中位数分别为48毫克(四分位间距:20 - 126)和75毫克(36 - 170),疼痛患者分别为50毫克(25 - 120)和57毫克(25 - 124)。
呼吸困难、相对年轻以及死亡前第7天口服吗啡当量剂量<50毫克可预测最后7天口服吗啡当量剂量增加。我们的研究结果可能有助于肿瘤学家更准确地告知患者预期的阿片类药物需求量,从而缓解他们的临终焦虑。